Mirubedis (Rivaroxaban)

Rivaroxaban, the active ingredient in Mirubedis, is a Direct Factor Xa inhibitor presented as an oral tablet for oral use. It is used to prevent stroke and systemic embolism in non‑valvular atrial fibrillation, to treat and prevent recurrence of deep vein thrombosis and pulmonary embolism, and to reduce the risk of postoperative DVT after orthopedic surgery.

GNH USA supplies Mirubedis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare institutions worldwide through reliable logistics.

Rivaroxaban is indicated for several thromboembolic conditions, acting as an anticoagulant to reduce clot formation.

- Non‑valvular atrial fibrillation: prevention of stroke and systemic embolism in patients with irregular heart rhythm. - Deep vein thrombosis (DVT) and pulmonary embolism (PE): treatment and secondary prevention of clot recurrence. - Orthopedic surgery (hip or knee replacement): prophylaxis of postoperative DVT to lower the risk of clot formation after major joint procedures.

Rivaroxaban may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Bleeding gums - Nosebleeds - Easy bruising - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Spontaneous intracranial hemorrhage - Severe gastrointestinal bleeding - Allergic skin reactions such as Stevens‑Johnson syndrome - Significant elevation of liver enzymes

Before initiating therapy, clinicians should evaluate patient‑specific factors that may increase bleeding risk.

- Renal impairment: assess kidney function and adjust therapy as needed. - Hepatic disease: avoid use in patients with severe liver dysfunction. - Concomitant antiplatelet therapy: increase bleeding risk; monitor closely. - Surgery or invasive procedures: discontinue prior to procedure according to clinical guidance. - Pregnancy and lactation: use only if benefits outweigh risks; limited data available. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can modify its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase rivaroxaban exposure and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy, increasing clot risk. - Combined use with other anticoagulants (e.g., warfarin, heparin): additive anticoagulant effect.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): may modestly increase bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): elevate gastrointestinal bleeding risk. - SSRIs and SNRIs: may enhance bleeding tendency.